Novonesis A/S/€NSISB

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Novonesis A/S

Novonesis A/S is a biotechnology company formed in January 2024 through the merger of Novozymes and Chr. Hansen. Headquartered in Lyngby, Denmark, the company specializes in developing biosolutions, including enzymes, functional proteins, and microorganisms, serving over 30 industries such as food and beverage, agriculture, and pharmaceuticals. With a global presence encompassing more than 23 manufacturing sites and nearly 40 R&D and application centers, Novonesis employs approximately 10,000 individuals worldwide. The company is committed to sustainability, aiming for carbon neutrality by 2050 and a 75% reduction in scope 1 and 2 emissions by 2030. Novonesis leverages its extensive expertise to create innovative biosolutions that address global challenges in health, nutrition, and environmental sustainability.

Ticker

€NSISB
Sector

Primary listing

XGAT

Employees

10,582

Headquarters

Lyngby, Denmark

Novonesis A/S Metrics

BasicAdvanced
€24B
26.26
€1.99
0.55
€0.86
1.65%

Bulls say / Bears say

Robust bioenergy demand in India and Latin America helped offset negative currency effects, demonstrating diversified growth drivers (Reuters)
Management reiterated ambitious long-term targets of 6–9% compound annual revenue growth through 2030 and a 39% core profit margin, underlining confidence in strategic direction (Reuters)
Strategic exit from Russia earlier this year had only a modest impact on sales, reflecting disciplined portfolio optimization toward more scalable markets (Reuters)
Profit margins in Q2 fell short of market expectations as currency fluctuations and tariff-related costs eroded returns (Reuters)
The stock slid about 7% on weaker-than-expected Q2 results, highlighting investor sensitivity to near-term performance (Reuters) (Reuters)
Heavy reliance on bioenergy markets in emerging regions exposes the company to policy and pricing volatility, potentially impacting future revenue stability (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €NSISB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs